

Chao-Hung Hung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7969422/publications.pdf>

Version: 2024-02-01

100
papers

2,537
citations

257101

24
h-index

223531

46
g-index

108
all docs

108
docs citations

108
times ranked

3325
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 412-418.	1.8	287
2	Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients. <i>Gastroenterology</i> , 2007, 133, 1466-1474.	0.6	204
3	Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. <i>Journal of Gastroenterology</i> , 2003, 38, 153-157.	2.3	179
4	Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. <i>Cancer</i> , 2006, 107, 2212-2222.	2.0	145
5	Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. <i>World Journal of Gastroenterology</i> , 2010, 16, 2265.	1.4	106
6	Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. <i>International Journal of Cancer</i> , 2011, 128, 2344-2352.	2.3	85
7	Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. <i>International Journal of Cancer</i> , 2016, 138, 714-720.	2.3	71
8	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	0.8	69
9	MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	64
10	Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 727-732.	1.4	63
11	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	0.8	60
12	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	1.9	46
13	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. <i>Journal of Hepatology</i> , 2014, 60, 1127-1134.	1.8	45
14	Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1553-1559.	1.4	41
15	Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. <i>Liver International</i> , 2009, 29, 1086-1093.	1.9	38
16	Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2154-2163.	1.3	37
17	Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. <i>Liver International</i> , 2016, 36, 1793-1799.	1.9	34
18	Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 525-533.	2.0	32

#	ARTICLE	IF	CITATIONS
19	Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C. <i>Translational Oncology</i> , 2014, 7, 503-507.	1.7	31
20	Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. <i>Liver International</i> , 2006, 26, 1079-1086.	1.9	29
21	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	1.9	29
22	A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 696-699.	1.3	28
23	Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2803-2812.e2.	2.4	28
24	Viral Etiology of Hepatocellular Carcinoma and HCV Genotypes in Taiwan. <i>Intervirology</i> , 2006, 49, 76-81.	1.2	27
25	Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 363-371.	0.8	27
26	Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1307-1314.	1.4	25
27	Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 512-521.	0.8	24
28	Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. <i>Scientific Reports</i> , 2018, 8, 16611.	1.6	24
29	Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2989-2997.e3.	2.4	23
30	Complete Remission of Nephrotic Syndrome of Hepatitis B Virus-associated Membranous Glomerulopathy After Lamivudine Monotherapy. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 869-873.	0.8	21
31	Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1676.	1.0	20
32	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.2	19
33	Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1404-1412.	1.0	18
34	Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 568-575.	1.4	17
35	Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1197-1205.	1.1	17
36	Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. <i>Scientific Reports</i> , 2020, 10, 7290.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. <i>Antiviral Research</i> , 2012, 93, 55-63.	1.9	16
38	Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 515-520.	0.8	16
39	Prognostic value of sarcopenia in patients with colorectal liver metastases undergoing hepatic resection. <i>Scientific Reports</i> , 2020, 10, 6459.	1.6	16
40	Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. <i>Liver Cancer</i> , 2022, 11, 22-37.	4.2	16
41	Impact of Steatosis on Long-Term Histological Outcome in Chronic Hepatitis C after Antiviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 483-489.	0.6	16
42	Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 1307-1311.	1.4	15
43	Hepatitis C core antigen highly correlated to HCVâ€™s RNA. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 684-688.	0.8	15
44	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE). <i>Journal of Infectious Diseases</i> , 2019, 220, 557-566.	1.9	15
45	The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. <i>World Journal of Surgery</i> , 2020, 44, 247-257.	0.8	15
46	Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. <i>Scientific Reports</i> , 2021, 11, 13543.	1.6	15
47	Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 746-750.	0.8	14
48	The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2019, 14, e0214323.	1.1	14
49	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	2.4	14
50	Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment in naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1695-1706.	1.9	14
51	Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. <i>PLoS ONE</i> , 2020, 15, e0231102.	1.1	13
52	Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. <i>PLoS ONE</i> , 2020, 15, e0242113.	1.1	13
53	Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 833-840.	0.8	12
54	Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. <i>Liver Cancer</i> , 2018, 7, 312-322.	4.2	12

#	ARTICLE	IF	CITATIONS
55	Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 278-283.	0.8	11
56	Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 442-449.	1.4	11
57	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
58	Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. <i>BMC Gastroenterology</i> , 2021, 21, 259.	0.8	11
59	Role of Viral Genotypes and Hepatitis B Viral Mutants in the Risk of Hepatocellular Carcinoma Associated with Hepatitis B and C Dual Infection. <i>Intervirolgy</i> , 2013, 56, 316-324.	1.2	10
60	Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. <i>Scientific Reports</i> , 2021, 11, 1365.	1.6	10
61	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	1.4	10
62	Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. <i>OncoTargets and Therapy</i> , 2014, 7, 829.	1.0	9
63	Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 197-203.	0.8	9
64	Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0229994.	1.1	9
65	Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor- κ B in chronic hepatitis C. <i>Liver International</i> , 2008, 28, 339-346.	1.9	8
66	Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. <i>Scientific Reports</i> , 2019, 9, 7086.	1.6	8
67	High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1593-1600.	0.8	8
68	Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. <i>Journal of Viral Hepatitis</i> , 2020, 27, 866-872.	1.0	8
69	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	1.6	8
70	Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. <i>BMC Gastroenterology</i> , 2016, 16, 73.	0.8	7
71	MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. <i>Scientific Reports</i> , 2016, 6, 33816.	1.6	7
72	Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. <i>Biomedical Journal</i> , 2022, 45, 788-797.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. <i>Hepatology International</i> , 2013, 7, 477-488.	1.9	6
74	Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 847-853.	0.8	6
75	A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir. <i>Hepatology International</i> , 2021, 15, 310-317.	1.9	6
76	Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area. <i>Hepatology</i> , 2013, 57, 2089-2090.	3.6	5
77	Hepatic Interferon Receptor Mrna Expression: Clinical Relevance and Its Relationship with Effectiveness of Interferon plus Ribavirin Therapy in Patients with Genotype 1B Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006, 11, 17-23.	0.6	5
78	Amino Acid Substitutions in the Core Region Associate with Insulin Resistance in Chronic Hepatitis C. <i>Intervirology</i> , 2013, 56, 166-171.	1.2	4
79	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	1.6	4
80	Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	4
81	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	1.9	4
82	Community-Based Screening for Hepatitis B and C Infectivity Using Two Quantitative Antigens to Identify Endemic Townships. <i>Viruses</i> , 2022, 14, 304.	1.5	4
83	Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. <i>Antiviral Therapy</i> , 2006, 11, 483-9.	0.6	4
84	Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 652-658.	0.8	3
85	Did AFP save ultrasonography in community screening?. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 583-587.	0.8	3
86	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.4	3
87	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	1.4	3
88	Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2911-2916.	1.4	3
89	Hepatic <i>Clostridium Perfringens</i> Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case. <i>Case Reports in Oncology</i> , 2021, 14, 906-911.	0.3	3
90	Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 532-537.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. <i>Journal of Viral Hepatitis</i> , 2020, 27, 505-513.	1.0	2
92	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	0.8	2
93	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	1.5	2
94	Acute hepatitis B virus superinfection in a Taiwanese patient with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2004, 103, 302-5.	0.8	2
95	Prognostic factors of radiofrequency ablation therapy for liver metastases from colorectal cancer. <i>Advances in Digestive Medicine</i> , 2019, 6, 101-108.	0.1	1
96	The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. <i>Biomedical Journal</i> , 2020, , .	1.4	1
97	The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir. <i>Viruses</i> , 2022, 14, 362.	1.5	1
98	Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. <i>Viruses</i> , 2022, 14, 1189.	1.5	1
99	Revisiting the accuracy of splenomegaly by sonography in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, 7, 30-35.	0.1	0
100	Esophageal perforation caused by a central venous catheter: A case report and literature review. <i>Advances in Digestive Medicine</i> , 2020, 7, 93-96.	0.1	0